Gastric Cancer Clinical Trials
A listing of Gastric Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 542 clinical trials
A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies. This investigational intervention treatment uses a single biological drug and is conducted in two parts. Part 1: INCAGN02385 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose …
- 383 views
- 10 May, 2022
- 4 locations
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with advanced malignancies. This investigational intervention treatment uses a single biological drug and is conducted in two parts. Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with …
- 262 views
- 10 May, 2022
- 4 locations
Different Endoscopic Gastric Cancer Risk Assessments
Kimura-Takamoto classification and EGGIM score can evaluate the risk of gastric cancer in patients, only in cross-sectional studies, it is not clear the diagnostic value of risk assessment in population
- 0 views
- 04 Oct, 2022
- 1 location
PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
"This is an international, multicenter, randomized, double-blind phase III study, plans to recruit 680 patients who received radical gastrectomy (R0, D2 or higher lymphadenectomy) with postoperative pathological stage II (T4aN0M0) or III (the 8th Edition American Joint Committee on Cancer [AJCC] Cancer Staging Manual) gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, …
- 4 views
- 04 Oct, 2022
- 25 locations
Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer (Neo-D2plus)
In this study the patients with histological evidence of adenocarcinoma of the stomach will be screened and, if eligible, submitted to neo-adjuvant chemotherapy (NAC). After conclusions of NAC and obtaining informed consent, they will be registered and randomized to receive surgical D2 vs. D2plus lymphadenectomy.
- 0 views
- 09 Feb, 2022
- 1 location
Immunonutritional Supplement After Total Gastrectomy in Patients With Stage III Gastric Cancer (CRUCIAL)
Gastric cancer patients with stage III will be randomized to immune nutrition support or control group at discharge after total gastrectomy. Patients will receive 6 months of immune nutrition
- 0 views
- 07 Oct, 2022
- 1 location
A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer
FNF-014 is a randomised, open-label, multicentre, parallel-group, phase 3 study in China to prove superiority of POF over S-1/docetaxel in postoperative adjuvant setting for pStage III gastric adenocarcinoma (including adenocarcinoma of the gastrooesophageal junction).
- 0 views
- 07 Feb, 2022
- 1 location
Risk of GAstric Adenocarcinoma After Cephalic Duodenopancreatectomy (RAGAD)
In view of the similarities of the surgical set-ups of partial gastrectomies and cephalic duodenopancreatectomies, and the increased risk of gastric cancer after early partial gastrectomy, it is
- 0 views
- 02 Mar, 2022
- 1 location
Vonoprazan-Based Triple Therapy in Comparison With Extended Sequential Therapy
This study aims to compare the efficacy of the current standard first-line anti-helicobacter pylori regimen, extended proton pump inhibitor-based sequential therapy, with that of vonoprazan-based triple therapy, through a randomized controlled trial.
- 0 views
- 23 May, 2022
- 1 location
Liquid Biopsies for the Personalized Management of Patients With Hereditary Diffuse Gastric Cancer
Activating somatic mutations and methylation profiles identified by liquid biopsies could identify CDH1 and CTNNA1 pathogenic variants carriers with invasive diffuse gastric cancer undetectable
- 0 views
- 27 Jan, 2021
- 1 location